Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes.
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic. The Danish drugmaker argues that the medications are too complex for those manufacturers to make safely.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and more.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
